MASH / MASLD

Topline results at week 52 show LPCN 1148 treatment met both the primary and hepatic encephalopathy endpoints in the management of cirrhosis.

The phase 2, proof-of-concept LEGEND trial achieved its primary efficacy endpoint for absolute reduction in HbA1c at week 24 with lanifibranor alone or in combination with empagliflozin.

An analysis of NHANES data suggests fewer than 3 in 10 patients with NAFLD received statin therapy, with only 50% with dyslipidemia receiving statins.

In the final installment in our 5-part video series, our pair of experts in hepatology touch upon how an approval for MASH would impact conversations around screening for asymptomatic patient populations.

In a landmark decision, the FDA has granted accelerated approval to resmetirom (Rezdiffra) for noncirrhotic NASH with moderate to advanced fibrosis.

The phase 3 ENLIGHTEN program will consist of 2 phase 3 trials evaluating the safety and efficacy of pegozafermin in patients with MASH.

Although abstinence is the safest approach, patients with SLD at low risk for advanced fibrosis can safely consume < 7.4 g/day of alcohol, equivalent to half of a standard US drinking unit.

Our February 2024 month in review highlights some of our top hepatology content from the past few weeks, including pipeline updates, phase 2/3 trial data, and new research in liver diseases.

Results suggest a high prevalence of fatty liver in adults with chronic HCV, which was significantly associated with central obesity, elevated blood pressure, and metabolic syndrome.

Survodutide, a dual agonist from Boehringer Ingelheim and Zealand Pharma, was associated with MASH resolution without worsening fibrosis among 83% of participants in a phase 2 trial.

NAFLD, ALD, liver fibrosis and cirrhosis, and recently diagnosed viral hepatitis were all associated with a greater risk of cataract.

Stigmatizing language was found on 88% of transplant center websites and was most prevalent when discussing alcohol-associated hepatitis and cirrhosis.

HealthFLD, a fully automated AI software for liver attenuation analysis from CT scans, has received FDA 510(k) clearance for use in the general population.

The analysis of several oral antidiabetic drugs revealed patients taking SGLT2 inhibitors had more NAFLD regression and fewer adverse liver-related outcomes.

The editorial team’s monthly recap of the top news in hepatology features research emphasizing women’s health in liver disease, a look at some less-recognized health benefits associated with achieving SVR, and promising approaches for preventing and treating hepatic conditions.

Screening for liver fibrosis was associated with sustained improvements in alcohol consumption, diet, weight, and exercise in individuals at risk of ALD and MASLD.

Patients with lean NAFLD had fewer metabolic comorbidities but maintained similar risk of NASH, cirrhosis, nonliver cancer, and mortality compared to their overweight and obese counterparts.

Following years of concerns about the stigmatization and inaccurate etiology of nonalcoholic fatty liver disease nomenclature, 2023 finally saw revised terminology for liver disease with the implementation of metabolic dysfunction-associated steatotic liver disease.

Findings were presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases and showed empagliflozin reduced liver fat content in both patients with T2DM and nondiabetic patients.

Loomba discusses how practices like his own are adapting to the new nomenclature in metabolic-associated liver disease.

Sanyal discusses the makeup of retatrutide and its potential for patients with fatty liver disease and comorbid metabolic conditions.

Post hoc phase 2b analyses suggest peogzafermin may benefit severe fibrosis regardless of MASH patients' cirrhosis status.

Retatrutide, an investigational triple-agonist therapy, may help resolve liver fat prior to progression to severe disease.

Investigators observe significantly greater 15-year survival rates after bariatric surgery among patients who achieve MASH resolution versus those who do not.

Performance metrics of NIS4, the ELF test, and FibroMeter VCTE met prespecified criteria for qualification for regulatory approval in stage 1 of the NIMBLE project's circulating biomarker workstream.